Education
About Us
Working with TipRanks
Follow Us
Paradigm Biopharmaceuticals Ltd. (PBIGF)
OTHER OTC:PBIGF
Total Valuation
Paradigm Biopharmaceuticals has a market cap or net worth of $77.60M. The enterprise value is $71.72M.
Market Cap$77.60M
Enterprise Value$71.72M
Share Statistics
Paradigm Biopharmaceuticals has 389,428,830 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding389,428,830
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Paradigm Biopharmaceuticals’s return on equity (ROE) is -2.46 and return on invested capital (ROIC) is -244.70%.
Return on Equity (ROE)-2.46
Return on Assets (ROA)-2.14
Return on Invested Capital (ROIC)-244.70%
Return on Capital Employed (ROCE)-2.71
Revenue Per Employee―
Profits Per Employee―
Employee Count―
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Paradigm Biopharmaceuticals is -1.45. Paradigm Biopharmaceuticals’s PEG ratio is -0.13.
PE Ratio-1.45
PS Ratio0.00
PB Ratio3.57
Price to Fair Value3.57
Price to FCF-1.29
Price to Operating Cash Flow-1.29
PEG Ratio-0.13
Income Statement
In the last 12 months, Paradigm Biopharmaceuticals had revenue of 65.80K and earned -58.65M in profits. Earnings per share was -0.20.
Revenue65.80K
Gross Profit56.81K
Operating Income-65.19M
Pretax Income-64.70M
Net Income-58.65M
EBITDA-64.54M
Earnings Per Share (EPS)-0.20
Cash Flow
In the last 12 months, operating cash flow was -23.14M and capital expenditures 14.92M, giving a free cash flow of -8.22M billion.
Operating Cash Flow-23.14M
Free Cash Flow-8.22M
Free Cash Flow per Share-0.02
Dividends & Yields
Paradigm Biopharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.14
52-Week Price Change-27.78%
50-Day Moving Average0.26
200-Day Moving Average0.21
Relative Strength Index (RSI)13.65
Average Volume (3m)650.00
Important Dates
Paradigm Biopharmaceuticals upcoming earnings date is Aug 29, 2025, TBA Not Confirmed.
Last Earnings DateFeb 27, 2025
Next Earnings DateAug 29, 2025
Ex-Dividend Date―
Financial Position
Paradigm Biopharmaceuticals as a current ratio of 7.22, with Debt / Equity ratio of 0.53%
Current Ratio7.22
Quick Ratio7.22
Debt to Market Cap0.00
Net Debt to EBITDA0.27
Interest Coverage Ratio-4.54K
Taxes
In the past 12 months, Paradigm Biopharmaceuticals has paid -6.05M in taxes.
Income Tax-6.05M
Effective Tax Rate0.09
Enterprise Valuation
Paradigm Biopharmaceuticals EV to EBITDA ratio is -1.05, with an EV/FCF ratio of -1.02.
EV to Sales1.03K
EV to EBITDA-1.05
EV to Free Cash Flow-1.02
EV to Operating Cash Flow-1.02
Balance Sheet
Paradigm Biopharmaceuticals has $24.78M in cash and marketable securities with AU$36.63K in debt, giving a net cash position of -$24.60M billion.
Cash & Marketable Securities$24.78M
Total DebtAU$36.63K
Net Cash-$24.60M
Net Cash Per Share-$0.06
Tangible Book Value Per Share$0.07
Margins
Gross margin is 66.42%, with operating margin of -99077.69%, and net profit margin of -89138.58%.
Gross Margin66.42%
Operating Margin-99077.69%
Pretax Margin-98328.73%
Net Profit Margin-89138.58%
EBITDA Margin-98083.89%
EBIT Margin-98306.89%
Analyst Forecast
The average price target for Paradigm Biopharmaceuticals is $0.51, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$0.51
Price Target Upside292.31% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast―